Journal
LEUKEMIA
Volume 32, Issue 1, Pages 184-193Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2017.162
Keywords
-
Categories
Funding
- CIHR grant [MOP1304, MOP 110952, MOP133656]
- Leukemia and Lymphoma Society of Canada
- NSFC (China) [81372456]
- Fund for the 8th group of Fostering Talents in Jilin Province of China [JRZX8]
- China Scholarship Council [CSC 201506170134]
Ask authors/readers for more resources
A deeper understanding of the mechanisms that underlie aberrant signal transduction in B-cell cancers such as chronic lymphocytic leukemia (CLL) may reveal new treatment strategies. The lipid-activated nuclear receptor peroxisome proliferator-activated receptor delta (PPARd) accounts for a number of properties of aggressive cancers and was found to enhance Janus kinase (JAK)-mediated phosphorylation of signal transducer and activator of transcription (STAT) proteins in B lymphoma cell lines and primary CLL cells. Autocrine production of cytokines such as IL10 and interferon-beta was not increased by PPARd but signaling responses to these cytokines were amplified and associated with increased cholesterol biosynthesis and plasma membrane levels. Plasmalemmal cholesterol and STAT phosphorylation from type 1 interferons (IFNs) were increased by PPARd agonists, transgenes and exogenous cholesterol, and decreased by cyclodextrin, PPARD deletion and chemical PPARd inhibitors. Functional consequences of PPAR delta-mediated perturbation of IFN signaling included impaired upregulation of co-stimulatory molecules. These observations suggest PPARd modulates signaling processes in malignant B cells in part by altering cholesterol metabolism and changes the outcomes of signaling from cytokines such as IFNs. PPARd antagonists may have therapeutic activity as anti-leukemic signal transduction modulators.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available